A New Take On Growth Factor Signaling In Tamoxifen Resistance

[News]

Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.

More... (http://www.medicalnewstoday.com/articles/155218.php)